Genomma Lab posted 5.0% net sales growth and 12.0% EBITDA increase in Q1 2025, with strong free cash flow and margin expansion, despite US and Argentina headwinds. Management targets low-teen sales growth and a 24% EBITDA margin mid-term.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Earlier from Genomma Lab Internacional Sab De Cv Class B
